Novartis AG
NVS
$164.66
$1.991.22%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.38% | 11.86% | 12.02% | 11.30% | 10.73% |
| Total Other Revenue | 52.46% | 49.52% | 46.35% | 18.94% | 15.16% |
| Total Revenue | 9.57% | 12.88% | 12.95% | 11.50% | 10.85% |
| Cost of Revenue | 6.28% | 10.91% | 9.48% | 6.75% | 6.61% |
| Gross Profit | 10.66% | 13.51% | 14.07% | 13.12% | 12.32% |
| SG&A Expenses | 5.36% | 6.57% | 5.57% | 2.76% | 0.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -22.01% | -172.69% | -92.81% | 2.82% | 24.22% |
| Total Operating Expenses | 7.18% | 10.12% | 6.52% | 5.26% | 4.33% |
| Operating Income | 14.78% | 18.20% | 27.31% | 26.50% | 28.22% |
| Income Before Tax | 19.88% | 28.96% | 43.21% | 53.29% | 49.51% |
| Income Tax Expenses | 40.21% | 108.82% | 142.01% | 230.87% | 208.71% |
| Earnings from Continuing Operations | 16.99% | 22.34% | 35.23% | 41.16% | 39.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 750.00% | 150.00% | 900.00% | 66.67% | 150.00% |
| Net Income | 17.11% | -18.24% | -15.59% | -15.65% | -19.59% |
| EBIT | 14.78% | 18.20% | 27.31% | 26.50% | 28.22% |
| EBITDA | 12.28% | 15.18% | 20.48% | 18.38% | 17.58% |
| EPS Basic | 21.82% | -14.70% | -12.56% | -13.28% | -17.72% |
| Normalized Basic EPS | 16.57% | 22.71% | 32.19% | 31.09% | 30.95% |
| EPS Diluted | 21.54% | -14.76% | -12.68% | -13.39% | -17.71% |
| Normalized Diluted EPS | 16.63% | 22.70% | 32.15% | 31.02% | 30.84% |
| Average Basic Shares Outstanding | -3.97% | -3.81% | -3.35% | -2.90% | -2.76% |
| Average Diluted Shares Outstanding | -4.00% | -3.80% | -3.30% | -2.83% | -2.66% |
| Dividend Per Share | 20.81% | -1.44% | -1.44% | -1.44% | -1.44% |
| Payout Ratio | -0.12% | 0.25% | 0.21% | 0.76% | 0.31% |